Impact of Social Determinants of Health and Novel Therapies on the Outcomes of Relapsed and Refractory Diffuse Large B Cell Lymphoma

被引：0
|
作者：
Lin, Chenyu [1 ,2 ]
Scobie, Micaela R. [3 ]
Anderson, Clare E. [2 ,4 ]
Friedman, Daphne R. [2 ,3 ,5 ]
Kelley, Michael J. [2 ,3 ,5 ]
Rodgers, Thomas D. [1 ,2 ]
机构：
[1] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Sch Med, Durham, NC USA
[2] Durham VA Med Ctr, Durham, NC USA
[3] Natl Oncol Program, Dept Vet Affairs, Washington, DC USA
[4] Duke Univ, Dept Med, Sch Med, Durham, NC USA
[5] Duke Univ, Div Med Oncol, Sch Med, Durham, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178803
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [2] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
    Crombie, Jennifer L.
    Jun, Monika
    Wang, Tongsheng
    Mutebi, Alex
    Wang, Anthony
    Chhibber, Anindit
    Kamalakar, Rajesh
    Ukropec, Jon
    Blaedel, Julie
    Kalsekar, Anupama
    [J]. LEUKEMIA & LYMPHOMA, 2024,
  • [3] Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma
    Skrabek, R.
    Assouline, S.
    Christofides, A.
    MacDonald, D.
    Prica, A.
    Sangha, R.
    Matthews, B. A.
    Sehn, L. H.
    [J]. CURRENT ONCOLOGY, 2019, 26 (04) : 253 - 265
  • [4] Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
    Desai, Sanjal H.
    Mwangi, Raphael
    Smith, Alexandra N.
    Maurer, Matthew J.
    Farooq, Umar
    King, Rebecca L.
    Cerhan, James R.
    Feldman, Andrew L.
    Habermann, Thomas M.
    Thompson, Carrie A.
    Wang, Yucai
    Ansell, Stephen M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 39 - 49
  • [5] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [6] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [7] Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
    Sawalha, Yazeed
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [8] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    [J]. HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [9] Blinatumomab in relapsed/refractory diffuse large B cell lymphoma
    Van Dijck, Ruben
    Janssens, Ann
    Dierickx, Daan
    Delforge, Michel
    Gheysens, Olivier
    Tousseyn, Thomas
    Verhoef, Gregor
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 (10) : 1759 - 1762
  • [10] Blinatumomab in relapsed/refractory diffuse large B cell lymphoma
    Ruben Van Dijck
    Ann Janssens
    Daan Dierickx
    Michel Delforge
    Olivier Gheysens
    Thomas Tousseyn
    Gregor Verhoef
    [J]. Annals of Hematology, 2017, 96 : 1759 - 1762
12345